deucravacitinib
FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, Immunology and inflammation, Otezla, psoriasis
0 Comment
X
FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib
https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/
Failed IBD trial dents confidence in BMS’ deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis
0 Comment
X
Failed IBD trial dents confidence in BMS’ deucravacitinib
https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rival
Richard Staines
Amgen, Bristol-Myers Squibb, deucravacitinib, psoriasis
0 Comment
X
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rival
https://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/